Insulet (NSDQ:PODD) announced today that its corporate headquarters and manufacturing facility will be powered by solar-based, renewable energy. The Acton, Mass.-based facility is set to turn to the new energy source, beginning this week. The company covered its 58,000 square-foot manufacturing facility with approximately 2,800 solar panels to, during optimal climate conditions, generate enough energy to […]
Insulet resumes next-gen Omnipod pivotal study following software issues
Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly. The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential […]
Insulet prices $500m public offering
Insulin management technology developer Insulet (NSDQ:PODD) announced that it priced a $500 million common stock offering. The Acton, Mass.-based company set the price of its common stock at $211 per share, with more than 2.3 million shares set to be sold. Insulet also granted underwriters a 30-day option to purchase up to 355,450 additional shares. Morgan […]
Insulet posts mixed bag Q1
Insulet (NSDQ:PODD) shares dropped slightly today on first-quarter results that topped the consensus revenue forecast but came up short on earnings. The Acton, Mass.-based insulin management technology developer posted losses of -$2.1, or -3¢ per share, on sales of $198 million for the three months ended March 31, 2020, for a bottom-line slide into losses from […]
DHS warns on Insulet Omnipod
The U.S. Dept. of Homeland Security (DHS) issued a medical advisory to warn of vulnerabilities with the Insulet (NSDQ:PODD) Omnipod insulin management system. According to the advisory, the affected insulin pumps are designed to communicate using a wireless RF with Insulet’s personal diabetes manager device, but the RF communication protocol does not properly implement authentication or […]
Insulet pauses OmniPod study due to software problem
Insulet (NSDQ:PODD) today said it is putting a halt on its pivotal study of its Omnipod Horizon Automated Glucose Control System because of a software anomaly. The company is correcting an issue that could result in the system using an incorrect glucose value that has the potential to impact insulin delivery, according to the company. Insulet […]
Insulet down after hours on Q4 sales beat, bottom-line slide
Insulet (NSDQ:PODD) shares took a further hit today after sliding in the market following the release of the company’s quarterly earnings. The company’s shares sunk after-hours yesterday on fourth-quarter results that beat the consensus forecast for revenue but appeared to miss on earnings. Today, shares of PODD are down -8.4% at $180.18 per share in mid-afternoon […]
Insulet partners with Abbott and Dexcom on automated insulin delivery
Abbott (NYSE:ABT) and Dexcom (NSDQ:DXCM) each announced today that they are partnering with Insulet (NSDQ:PODD) to feed blood glucose monitor data into an automated insulin delivery system. For Acton, Mass.–based Insulet, the agreements are a boost for its next-generation Omnipod Horizon automated insulin delivery system, which is presently an investigational device in the United States. The idea of […]
Insulet’s Omnipod Dash Personal Diabetes Managers have a glitch
Insulet (NSDQ:PODD) is issuing a voluntary medical device correction for all of the smartphone-like Personal Diabetes Managers that came with its next-gen Omnipod Dash insulin management system, the company announced today. During its ongoing quality management process, Insulet officials discovered that the PDMs on rare occasions will suggest an inaccurate bolus amount based on a blood […]
The 10 greatest medtech advances of the 2010s
From disposable endoscopes to TAVR to robotic surgery, there’s a whole host of medtech advances widely available now that weren’t around much 10 years ago. “In terms of technological advances, I would put this past decade as one of the most important for medical technology. From connected devices and robotics, to advances in material sciences […]
Insulet Q3 earnings beat The Street despite bottom-line slide
Insulet (NSDQ:PODD) shares are rising today on third-quarter results that topped the consensus forecast, despite a dip in profits. The Acton, Mass.–based company posted profits of $852,000, or 1¢ per share, on sales of $192.1 million for the three months ended Sept. 30, for a 48.6% bottom-line slide on sales growth of 27.1%. Get the full […]
- 1
- 2
- 3
- …
- 19
- Next Page »
